Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Melanoma; Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Disease Attributes Disease Progression Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Melanoma Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplastic Processes Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Pathologic Processes Pathological Conditions, Signs and Symptoms Remission, Spontaneous Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Indiana University Simon Cancer Center

Indianapolis, Indiana, 46202, United States

About this study

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.

Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.

Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

≥ 18 years old at the time of informed consent
Ability to provide written informed consent and HIPAA authorization
Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Willingness to undergo phlebotomy for research blood samples

Exclusion criteria

Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Treatment and study plan

Blood collection for laboratory studies

Other

Peripheral whole blood will be collected

Data collection from medical record

Other

Clinical data such as demographics and cancer characteristics, history and treatment will be collected

Primary outcomes

Number of blood samples collected

Time frame: 1 year

samples collected from metastatic melanoma and renal cell cancer patients

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Registry information

Official study title

Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression

Important dates

Study start: 2004
Primary completion: 2027
Study completion: 2027
First posted: Nov 2, 2018
Registry last updated: Oct 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting